» Articles » PMID: 31798939

Gut Microbiota Composition During a 12-week Intervention with Delayed-release Dimethyl Fumarate in Multiple Sclerosis - a Pilot Trial

Overview
Date 2019 Dec 5
PMID 31798939
Citations 25
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: Patients with multiple sclerosis may have a distinct gut microbiota profile. Delayed-release dimethyl fumarate is an orally administered drug for relapsing-remitting multiple sclerosis, which has been associated with gastrointestinal side-effects in some patients.

Objectives: The purpose of this study was to determine if dimethyl fumarate alters the abundance and diversity of commensal gut bacteria, and if these changes are associated with gastrointestinal side-effects.

Methods: Thirty-six patients with relapsing-remitting multiple sclerosis received either dimethyl fumarate ( = 27) or an injectable multiple sclerosis disease-modifying therapy (glatiramer acetate or interferons,  = 9) for 12 weeks. Stool samples were collected at baseline, two and 12 weeks. We included 165 healthy individuals as controls.

Results: At baseline, 16 microbial genera were altered in multiple sclerosis patients compared with healthy controls. In the dimethyl fumarate-treated patients ( = 21) we observed a trend of reduced Actinobacteria ( = 0.03, Q = 0.24) at two weeks, mainly driven by ( = 0.06, Q = 0.69). At 12 weeks, we observed an increased abundance of Firmicutes ( = 0.02, Q = 0.09), mostly driven by ( = 0.01, Q = 0.48).

Conclusions: This pilot study did not detect a major effect of dimethyl fumarate on the gut microbiota composition, but we observed a trend towards normalization of the low abundance of butyrate-producing after 12 weeks treatment. The study was underpowered to link microbiota to gastrointestinal symptoms.

Citing Articles

Perturbations in gut microbiota composition in patients with autoimmune neurological diseases: a systematic review and meta-analysis.

Deng X, Gong X, Zhou D, Hong Z Front Immunol. 2025; 16:1513599.

PMID: 39981228 PMC: 11839609. DOI: 10.3389/fimmu.2025.1513599.


The role of the "gut microbiota-mitochondria" crosstalk in the pathogenesis of multiple sclerosis.

Tian H, Huang D, Wang J, Li H, Gao J, Zhong Y Front Microbiol. 2024; 15:1404995.

PMID: 38741740 PMC: 11089144. DOI: 10.3389/fmicb.2024.1404995.


Impact of Disease-Modifying Therapies on Gut-Brain Axis in Multiple Sclerosis.

Negro I, Pez S, Versace S, Marziali A, Gigli G, Tereshko Y Medicina (Kaunas). 2024; 60(1).

PMID: 38276041 PMC: 10818907. DOI: 10.3390/medicina60010006.


Disease-modifying therapies used to treat multiple sclerosis and the gut microbiome: a systematic review.

Tsai C, Jette S, Tremlett H J Neurol. 2023; 271(3):1108-1123.

PMID: 38078977 DOI: 10.1007/s00415-023-12107-0.


Unraveling the Gut-Brain Axis in Multiple Sclerosis: Exploring Dysbiosis, Oxidative Stress, and Therapeutic Insights.

Sharifa M, Ghosh T, Daher O, Bhusal P, Alaameri Y, Naz J Cureus. 2023; 15(10):e47058.

PMID: 38022314 PMC: 10644699. DOI: 10.7759/cureus.47058.


References
1.
Chen H, Assmann J, Krenz A, Rahman M, Grimm M, Karsten C . Hydroxycarboxylic acid receptor 2 mediates dimethyl fumarate's protective effect in EAE. J Clin Invest. 2014; 124(5):2188-92. PMC: 4001545. DOI: 10.1172/JCI72151. View

2.
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson E . Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018; 555(7698):623-628. PMC: 6108420. DOI: 10.1038/nature25979. View

3.
Berer K, Gerdes L, Cekanaviciute E, Jia X, Xiao L, Xia Z . Gut microbiota from multiple sclerosis patients enables spontaneous autoimmune encephalomyelitis in mice. Proc Natl Acad Sci U S A. 2017; 114(40):10719-10724. PMC: 5635914. DOI: 10.1073/pnas.1711233114. View

4.
Gold R, Kappos L, Arnold D, Bar-Or A, Giovannoni G, Selmaj K . Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012; 367(12):1098-107. DOI: 10.1056/NEJMoa1114287. View

5.
Mizuno M, Noto D, Kaga N, Chiba A, Miyake S . The dual role of short fatty acid chains in the pathogenesis of autoimmune disease models. PLoS One. 2017; 12(2):e0173032. PMC: 5325617. DOI: 10.1371/journal.pone.0173032. View